Clinical case conference: Unobserved "home" induction onto buprenorphine

Joshua Lee, Jennifer McNeely, Ellie Grossman, Frank Vocci, David A. Fiellin

Research output: Contribution to journalArticle

Abstract

Unobserved or "home" buprenorphine induction has become a common clinical practice. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This clinical case summarizes an unobserved induction onto buprenorphine in a typical new patient. We review the core issues surrounding patient selection, feasibility, logistics, safety, and effectiveness of unobserved buprenorphine induction. Prescribers, treatment providers, policy makers, and patients should weigh the benefits of observed induction (maximum clinical supervision) with the reduced resource burden, flexibility, and comparable safety of unobserved induction.

Original languageEnglish (US)
Pages (from-to)309-314
Number of pages6
JournalJournal of Addiction Medicine
Volume8
Issue number5
DOIs
StatePublished - Sep 1 2014

Fingerprint

Buprenorphine
Safety
Office Visits
Administrative Personnel
Patient Selection
Therapeutics

Keywords

  • Buprenorphine
  • Induction
  • Medication adherence
  • Opioid-related disorders
  • Patient compliance
  • Unobserved induction

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Clinical case conference : Unobserved "home" induction onto buprenorphine. / Lee, Joshua; McNeely, Jennifer; Grossman, Ellie; Vocci, Frank; Fiellin, David A.

In: Journal of Addiction Medicine, Vol. 8, No. 5, 01.09.2014, p. 309-314.

Research output: Contribution to journalArticle

Lee, Joshua ; McNeely, Jennifer ; Grossman, Ellie ; Vocci, Frank ; Fiellin, David A. / Clinical case conference : Unobserved "home" induction onto buprenorphine. In: Journal of Addiction Medicine. 2014 ; Vol. 8, No. 5. pp. 309-314.
@article{ca481548f2fe4e11b5f61e7eb3472fdc,
title = "Clinical case conference: Unobserved {"}home{"} induction onto buprenorphine",
abstract = "Unobserved or {"}home{"} buprenorphine induction has become a common clinical practice. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This clinical case summarizes an unobserved induction onto buprenorphine in a typical new patient. We review the core issues surrounding patient selection, feasibility, logistics, safety, and effectiveness of unobserved buprenorphine induction. Prescribers, treatment providers, policy makers, and patients should weigh the benefits of observed induction (maximum clinical supervision) with the reduced resource burden, flexibility, and comparable safety of unobserved induction.",
keywords = "Buprenorphine, Induction, Medication adherence, Opioid-related disorders, Patient compliance, Unobserved induction",
author = "Joshua Lee and Jennifer McNeely and Ellie Grossman and Frank Vocci and Fiellin, {David A.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1097/ADM.0000000000000060",
language = "English (US)",
volume = "8",
pages = "309--314",
journal = "Journal of Addiction Medicine",
issn = "1932-0620",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clinical case conference

T2 - Unobserved "home" induction onto buprenorphine

AU - Lee, Joshua

AU - McNeely, Jennifer

AU - Grossman, Ellie

AU - Vocci, Frank

AU - Fiellin, David A.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Unobserved or "home" buprenorphine induction has become a common clinical practice. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This clinical case summarizes an unobserved induction onto buprenorphine in a typical new patient. We review the core issues surrounding patient selection, feasibility, logistics, safety, and effectiveness of unobserved buprenorphine induction. Prescribers, treatment providers, policy makers, and patients should weigh the benefits of observed induction (maximum clinical supervision) with the reduced resource burden, flexibility, and comparable safety of unobserved induction.

AB - Unobserved or "home" buprenorphine induction has become a common clinical practice. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This clinical case summarizes an unobserved induction onto buprenorphine in a typical new patient. We review the core issues surrounding patient selection, feasibility, logistics, safety, and effectiveness of unobserved buprenorphine induction. Prescribers, treatment providers, policy makers, and patients should weigh the benefits of observed induction (maximum clinical supervision) with the reduced resource burden, flexibility, and comparable safety of unobserved induction.

KW - Buprenorphine

KW - Induction

KW - Medication adherence

KW - Opioid-related disorders

KW - Patient compliance

KW - Unobserved induction

UR - http://www.scopus.com/inward/record.url?scp=84921859130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921859130&partnerID=8YFLogxK

U2 - 10.1097/ADM.0000000000000060

DO - 10.1097/ADM.0000000000000060

M3 - Article

C2 - 25254668

AN - SCOPUS:84921859130

VL - 8

SP - 309

EP - 314

JO - Journal of Addiction Medicine

JF - Journal of Addiction Medicine

SN - 1932-0620

IS - 5

ER -